International Alliance for Personalised Medicine, shared on LinkedIn:
”IPM Brief / Issue 25 is now available
August may have been a quieter month for many of us, but healthcare certainly did not go on holiday.
The latest edition of the IPM Brief looks back at the developments that shaped the global health and personalised medicine landscape over the summer, from major shifts in pharmaceutical pricing and manufacturing to new regulatory approaches, emerging technologies and the growing pressure on health systems to adapt.
This week’s issue explores:
- Most-Favoured-Nation drug pricing and the growing role of pharmaceutical prices in international policy and trade negotiations
- $500 billion in pharmaceutical manufacturing and research commitments as companies respond to tariffs and political pressure for local production
- The implementation of the EU AI Act and what its evolving timeline means for AI-enabled medical technologies
- The Ebola outbreak in the Democratic Republic of the Congo, highlighting the gap between vaccine availability and preparedness for emerging viral threats
- The first mRNA seasonal influenza vaccine, marking another step towards mRNA as a broader vaccine platform
- A new targeted treatment for pancreatic cancer, offering a potential breakthrough for one of the most difficult cancers to treat
- The termination of a personalised mRNA cancer vaccine trial, and what the result tells us about evidence, tumour biology and the limits of technological optimism
- The global GLP-1 market, where high demand, affordability challenges and the growth of illicit supply are increasingly colliding
- Front-of-pack food labelling, and the role of regulation, industry influence and public pressure in shaping prevention policy
- The changing architecture of global health assistance, as nearly $2 billion in US funding moves towards faith-based and community organisations across more than 20 countries
Across these stories, one question keeps returning: what happens when scientific innovation meets the realities of policy, markets, regulation, infrastructure and access?
At IAPM, we believe that understanding these connections is essential to understanding the future of personalised medicine.
The IPM Brief goes beyond reporting individual developments. Twice a week, it connects science, health policy, economics and implementation to examine what emerging changes could mean for healthcare systems, innovation and, ultimately, patients.
Issue 25 is now available.
Not yet subscribed? Join our growing community and receive the IPM Brief directly in your inbox twice every week.
Evidence-based. Globally focused. Patient-centred.”
Other articles about public health on OncoDaily.